Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation

Table 4 Disease-free survival and overall survival rates according to various criteria

Criteria		Disease-free survival			Overall survival
		3 yr	5 yr	P-value	3 yr	5 yr	P-value
Milan	Within (n = 130)	0.880	0.867	0.009	0.808	0.798	0.137
	Beyond (n = 81)	0.730	0.704		0.733	0.706
UCSF	Within (n = 150)	0.881	0.869	0.001	0.822	0.813	0.009
	Beyond (n = 61)	0.681	0.645		0.677	0.643
CMC	Within (n = 138)	0.899	0.886	< 0.001	0.840	0.818	0.006
	Beyond (n = 71)	0.682	0.656		0.663	0.663
TNM	T1 (n = 80)	0.890	0.870	0.190	0.830	0.830	0.394
	T2 (n = 123)	0.788	0.773		0.753	0.725
	T3 (n = 7)	0.571	0.571		0.556	0.556
BCLC	0 (n = 35)	0.943	0.902	< 0.001	0.882	0.882	0.005
	A (n = 80)	0.878	0.878		0.805	0.787
	B (n = 52)	0.854	0.854		0.878	0.826
	C (n = 44)	0.578	0.544		0.549	0.549
CLIP	0,1 (n = 88)	0.795	0.771	0.011	0.776	0.776	0.272
	2,3 (n = 106)	0.885	0.870		0.819	0.792
	4,5 (n = 12)	0.556	0.556		0.509	0.509

UCSF: University of California, San Francisco; CMC: Catholic Medical Center; BCLC: Barcelona Clinic Liver Cancer; CLIP: Cancer of the Liver Italian Program.